Results from a real-world study of patients (pts) with hormone-receptor (HR)-positive HER2-negative metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK 4/6i) in three institutions

CDK 4/6i combined with endocrine therapy have become the gold standard in HR-positive HER-negative MBC treatment. Pts included in randomized clinical trials (RCT) are often not representative of real population. Real word data (RWD) can be used to confirm reproducibility of evidence from RCTs in routine clinical practice. We report results from retrospective analysis of a RWD cohort of pts.